| Identification | Back Directory | [Name]
GALANIN (1-13)-SPANTIDE I | [CAS]
143868-20-6 | [Synonyms]
C7
C8
GALANIN (1-13)-SPANTIDE I
Galanin (1-13)-Spantide I
C7
GWTLNSAGYLLGPRPKPQQWFWLL-NH2
GALANIN (1-13) - SPANTIDE-NH2
GALANIN (1-13)-SPANTIDE AMIDE
Galanin (1-13)-Spantide I, C8
M.W. 2828.27 C138H199N35O30
galanin fragment 1-13-spantide i
Galanin (1-13) - Spantide I amide
GLY-TRP-THR-LEU-ASN-SER-ALA-GLY-TYR-LEU-LEU-GLY-PRO-D-ARG-PRO-LYS-PRO-GLN-GLN-D-TRP-PHE-D-TRP-LEU-LEU-NH2
H-GLY-TRP-THR-LEU-ASN-SER-ALA-GLY-TYR-LEU-LEU-GLY-PRO-D-ARG-PRO-LYS-PRO-GLN-GLN-D-TRP-PHE-D-TRP-LEU-LEU-NH2
GLY-TRP-THR-LEU-ASN-SER-ALA-GLY-TYR-LEU-LEU-GLY-PRO-HIS-ALA-ILE-ASP-ASN-HIS-ARG-SER-PHE-SER-ASP-LYS-HIS-GLY-LEU-THR-NH2: GWTLNSAGYLLGPHAIDNHRSFSDKHGLT-NH2
L-Leucinamide, glycyl-L-tryptophyl-L-threonyl-L-leucyl-L-asparaginyl-L-seryl-L-alanylglycyl-L-tyrosyl-L-leucyl-L-leucylglycyl-L-prolyl-D-arginyl-L-prolyl-L-lysyl-L-prolyl-L-glutaminyl-L-glutaminyl-D-tryptophyl-L-phenylalanyl-D-tryptophyl-L-leucyl- | [Molecular Formula]
C138H199N35O30 | [MDL Number]
MFCD00273999 | [MOL File]
143868-20-6.mol | [Molecular Weight]
2828.27 |
| Chemical Properties | Back Directory | [density ]
1.22 g/mL at 25 °C(lit.) | [storage temp. ]
−20°C | [form ]
Solid | [Sequence]
Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-Arg-Pro-Lys-Pro-Gln-Gln-Trp-Phe-Trp-Leu-Leu-NH2 |
| Hazard Information | Back Directory | [Uses]
Galanin (1-13)-spantide I is a chimeric peptide composed of the N-terminal fragment of galanin (amino acids 1-13) and spantide, a known substance P receptor antagonist. Galanin (1-13)-spantide I has a high affinity for spinal galanin receptor (Kd=1.16 nM). Galanin (1-13)-spantide I can be used to study the effects of galanin on feeding behavior[1][2]. | [References]
[1] Crawley J N, et al. Galanin receptor antagonists M40 and C7 block galanin-induced feeding[J]. Brain research, 1993, 600(2): 268-272. DOI:10.1016/0006-8993(93)91382-3
[2] Xu X J, et al. New high affinity peptide antagonists to the spinal galanin receptor[J]. British journal of pharmacology, 1995, 116(3): 2076-2080. DOI:10.1111/j.1476-5381.1995.tb16414.x |
|
|